
|Videos|January 7, 2014
The Utility of PET Imaging in Prostate Cancer
Author(s)Evan Y. Yu, MD
Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the utility of PET imaging for the treatment of patients with prostate cancer.
Advertisement
Clinical Pearls
Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the utility of PET imaging for the treatment of patients with prostate cancer.
- Recently, the US Centers for Medicare and Medicaid Services (CMS) decided to pay for fluorodeoxyglucose positron emission tomography (FDG-PET)
- FDG-PET maybe useful for both detection as well as imaging treatment response in metastatic castration-resistant disease
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































